Endothelial progenitor cells as a therapeutic option in intracerebral hemorrhage  

作　　者：Juan Pías-Peleteiro Francisco Campos José Castillo Tomás Sobrino 

机构地区：[1]Clinical Neurosciences Research Laboratory,Department of Neurology,Stroke Unit,University Clinical Hospital,Universidade de Santiago de Compostela,Health Research Institute of Santiago de Compostela (IDIS)

出　　处：《Neural Regeneration Research》2017年第4期558-561,共4页中国神经再生研究（英文版）

基　　金：supported by grants from the Spanish Ministry of Economy and Competitiveness(SAF2014-56336);the Instituto de Salud Carlos III(PI13/00292&PI14/01879);the Spanish Research Network on Cerebrovascular Diseases(RETICS INVICTUS;RD12/0014);the Xunta de Galicia(Department of Education,GRC2014/027);the European Union program FEDER;F.Campos(CP14/00154);TS(CP12/03121)are recipients of a research contract from Miguel Servet Program of Instituto de Salud Carlos III

摘　　要：Intracerebral hemorrhage （ICH） is the most severe cerebrovascular disease, which represents a leading cause of death and disability in developed countries. However, therapeutic options are limited, so is mandatory to investigate repairing processes after stroke in order to develop new therapeutic strategies able to promote brain repair processes. Therapeutic angiogenesis and vasculogenesis hold promise to improve outcome of ICH patients. In this regard, circulating endothelial progenitor cells （EPCs） have recently been suggested to be a marker of vascular risk and endothelial function. Moreover, EPC levels have been associated with good neurological and functional outcome as well as reduced residual hematoma volume in ICH patients. Finally, experimental and clinical studies indicate that EPC might mediate endothelial cell regeneration and neovascularization. Therefore, EPC-based therapy could be an excellent therapeutic option in ICH. In this mini-review, we discuss the present status of knowledge about the possible therapeutic role of EPCs in ICH, molecular mechanisms, and the future perspectives and strategies for their use in clinical practice.Intracerebral hemorrhage （ICH） is the most severe cerebrovascular disease, which represents a leading cause of death and disability in developed countries. However, therapeutic options are limited, so is mandatory to investigate repairing processes after stroke in order to develop new therapeutic strategies able to promote brain repair processes. Therapeutic angiogenesis and vasculogenesis hold promise to improve outcome of ICH patients. In this regard, circulating endothelial progenitor cells （EPCs） have recently been suggested to be a marker of vascular risk and endothelial function. Moreover, EPC levels have been associated with good neurological and functional outcome as well as reduced residual hematoma volume in ICH patients. Finally, experimental and clinical studies indicate that EPC might mediate endothelial cell regeneration and neovascularization. Therefore, EPC-based therapy could be an excellent therapeutic option in ICH. In this mini-review, we discuss the present status of knowledge about the possible therapeutic role of EPCs in ICH, molecular mechanisms, and the future perspectives and strategies for their use in clinical practice.

关 键 词：cellular therapy endothelial progenitor cells growth factors intracerebral hemorrhage NEUROREPAIR OUTCOME 

分 类 号：R743.34[医药卫生—神经病学与精神病学]